Biochemistry, molecular biology, and pharmacology of fatty acid synthase, an emerging therapeutic target and diagnosis/prognosis marker

Author(s): Liu H, Liu JY, Wu X, Zhang JT

Abstract

Fatty acid synthase (FAS), the sole mammalian enzyme capable of de novo fatty acid synthesis, is highly expressed in most human carcinomas. FAS is associated with poor prognosis in breast and prostate cancer, is elaborated into the blood of cancer patients, and its inhibition is selectively cytotoxic to human cancer cells. Thus, FAS and fatty acid metabolism in cancer has become a focus for the potential diagnosis and treatment of cancer. (Cancer Res 2006; 66(12): 5977-80)

Similar Articles

Clinicopathological significance of fatty acid synthase expression in carcinoma of the Ampulla of Vater

Author(s): Maekawa H, Ito T, Kushida T, Orita H, Sakurada M, et al.

Cancer Review: Cholangiocarcinoma

Author(s): Ghouri YA, Mian I, Blechacz B

Epidemiology of cholangiocarcinoma

Author(s): Bergguist A, von Seth E

Prognostic impact of lymph node metastasis in distal cholangiocarcinoma

Author(s): Kiriyama M, Ebata T, Aoba T, Kaneoka Y, Arai T, et al.

Prognositc factors for survival after curative resection of distal cholangiocarcinoma

Author(s): Kim HJ, Kim CY, Hur YH, Koh YS, Kim JC, et al.

Prognostic factors in patients with middle and distal bile duct cancers

Author(s): Kwon HJ, Kim SG, Chun JM, Lee WK, Hwang YJ

Prognostic significance of overexpression of c-Met oncoprotein in cholangiocarcinoma

Author(s): Miyamoto M, Ojima h, Iwasaki M, Shimizu H, Kokubu A, et al.

Survival rate of extrahepatic cholangiocarcinoma patients after surgical treatment in Thailand

Author(s): Pattanathien P, Khuntikeo N, Promthet S, Kamsa-Ard S

Distal cholangiocarcinoma

Author(s): Lad N, Kooby DA